Artios
Artios believe DNA damage response (DDR)-targeting therapies can play a significant role in the treatment of malignant disease, and they aim to take advantage of the full range of DDR therapeutic strategies to unlock new opportunities for patients. Artios' industry-leading expertise in this space has yielded a robust pipeline and platform with immense potential, which has led to collaborations with major pharma partners.
Latest Artios Content
Industry Insight
New Approaches for Cancer Therapies: Targeting the DNA Damage Response
We speak with Dr. Niall Martin, CEO of Artios Pharma, to learn more about the development of drugs to target the DNA damage response pathway in cancer.
Industry Insight
Cancer Research Horizons: Driving Innovation and Strengthening Academia–Industry Collaboration
In April 2022, Cancer Research UK unveiled Cancer Research Horizons, its new approach to driving innovation in the field. Technology Networks had the opportunity to speak with two members of Cancer Research Horizon’s executive leadership team to learn more about some of the cutting-edge experimental capabilities that will be used to interrogate cancer biology more thoroughly.
Advertisement
